---
document_datetime: 2025-12-02 06:17:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/potactasol.html
document_name: potactasol.html
version: success
processing_time: 0.1274363
conversion_datetime: 2025-12-29 19:18:15.408502
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Potactasol

[RSS](/en/individual-human-medicine.xml/65916)

##### Authorised

This medicine is authorised for use in the European Union

topotecan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Potactasol](#more-information-on-potactasol-1143)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Potactasol. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Potactasol.

Expand section

Collapse section

## What is Potactasol?

Potactasol is a medicine that contains the active substance topotecan. It is available as a powder to be made up into a solution for infusion (drip) into a vein.

Potactasol is a 'generic medicine'. This means that Potactasol is similar to a 'reference medicine' already authorised in the European Union (EU) called Hycamtin.

## What is Potactasol used for?

Potactasol is a cancer medicine. It is used on its own to treat patients with:

- metastatic cancer of the ovary (when the cancer has spread to other parts of the body). It is used after at least one other treatment has failed;
- small cell lung cancer, when the cancer has relapsed (come back). It is used when giving the original treatment again is not recommended.

It is also used together with cisplatin (another cancer medicine) to treat women with cancer of the cervix, when the cancer has come back after radiotherapy, or when the disease is at an advanced stage (the cancer has spread beyond the cervix).

The medicine can only be obtained with a prescription.

## How is Potactasol used?

Treatment with Potactasol should only be given under the supervision of a doctor experienced in the use of chemotherapy. Infusions should be carried out in a specialised cancer ward.

The dose of Potactasol to be used depends on the type of cancer that it is being used to treat and the patient's weight and height. When Potactasol is used on its own for ovarian cancer, it is given by infusion over 30 minutes. For both ovarian and lung cancer, Potactasol is given every day for five days with a three-week interval between the start of each course. Treatment may continue until the disease gets worse.

When used with cisplatin in cervical cancer, Potactasol is given as an infusion on days 1, 2 and 3 (with cisplatin given on day 1). This is repeated every 21 days for six courses or until the disease gets worse.

Doses of Potactasol may need to be adjusted or treatment delayed, depending on side effects. For full details, see the summary of product characteristics, also part of the EPAR.

## How does Potactasol work?

The active substance in Potactasol, topotecan, is a cancer medicine that belongs to the group 'topoisomerase inhibitors'. It blocks an enzyme called topoisomerase I, which is involved in the division of DNA. When the enzyme is blocked, the DNA strands break. This prevents the cancer cells from dividing and they eventually die. Potactasol also affects non?cancer cells, which causes side effects.

## How has Potactasol been studied?

The company has provided data from the published literature on topotecan. No additional studies were needed as Potactasol is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Hycamtin.

## What are the benefits and risks of Potactasol?

Because Potactasol is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Potactasol been approved?

The CHMP concluded that, in accordance with EU requirements, Potactasol has been shown to be comparable to Hycamtin. Therefore, the CHMP's view was that, as for Hycamtin, the benefit outweighs the identified risk. The Committee recommended that Potactasol be given marketing authorisation.

## Other information about Potactasol

The European Commission granted a marketing authorisation valid throughout the European Union for Potactasol to on 06 January 2011.

For more information about treatment with Potactasol, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Potactasol : EPAR - Summary for the public

English (EN) (80.31 KB - PDF)

**First published:** 17/01/2011

**Last updated:** 10/11/2015

[View](/en/documents/overview/potactasol-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-539)

български (BG) (108.51 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/bg/documents/overview/potactasol-epar-summary-public_bg.pdf)

español (ES) (86.32 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/es/documents/overview/potactasol-epar-summary-public_es.pdf)

čeština (CS) (105.51 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/cs/documents/overview/potactasol-epar-summary-public_cs.pdf)

dansk (DA) (85.91 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/da/documents/overview/potactasol-epar-summary-public_da.pdf)

Deutsch (DE) (87.31 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/de/documents/overview/potactasol-epar-summary-public_de.pdf)

eesti keel (ET) (85.28 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/et/documents/overview/potactasol-epar-summary-public_et.pdf)

ελληνικά (EL) (110.48 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/el/documents/overview/potactasol-epar-summary-public_el.pdf)

français (FR) (87.08 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/fr/documents/overview/potactasol-epar-summary-public_fr.pdf)

hrvatski (HR) (92.7 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/hr/documents/overview/potactasol-epar-summary-public_hr.pdf)

italiano (IT) (85.53 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/it/documents/overview/potactasol-epar-summary-public_it.pdf)

latviešu valoda (LV) (101.95 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/lv/documents/overview/potactasol-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (103.2 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/lt/documents/overview/potactasol-epar-summary-public_lt.pdf)

magyar (HU) (101.66 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/hu/documents/overview/potactasol-epar-summary-public_hu.pdf)

Malti (MT) (104.96 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/mt/documents/overview/potactasol-epar-summary-public_mt.pdf)

Nederlands (NL) (86.25 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/nl/documents/overview/potactasol-epar-summary-public_nl.pdf)

polski (PL) (107 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/pl/documents/overview/potactasol-epar-summary-public_pl.pdf)

português (PT) (86.46 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/pt/documents/overview/potactasol-epar-summary-public_pt.pdf)

română (RO) (102.09 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/ro/documents/overview/potactasol-epar-summary-public_ro.pdf)

slovenčina (SK) (104.54 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/sk/documents/overview/potactasol-epar-summary-public_sk.pdf)

slovenščina (SL) (92.56 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/sl/documents/overview/potactasol-epar-summary-public_sl.pdf)

Suomi (FI) (85.54 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/fi/documents/overview/potactasol-epar-summary-public_fi.pdf)

svenska (SV) (85.97 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

10/11/2015

[View](/sv/documents/overview/potactasol-epar-summary-public_sv.pdf)

## Product information

Potactasol : EPAR - Product Information

English (EN) (398 KB - PDF)

**First published:** 17/01/2011

**Last updated:** 20/01/2025

[View](/en/documents/product-information/potactasol-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-863)

български (BG) (551.06 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/bg/documents/product-information/potactasol-epar-product-information_bg.pdf)

español (ES) (419.63 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/es/documents/product-information/potactasol-epar-product-information_es.pdf)

čeština (CS) (501.04 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/cs/documents/product-information/potactasol-epar-product-information_cs.pdf)

dansk (DA) (434.41 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/da/documents/product-information/potactasol-epar-product-information_da.pdf)

Deutsch (DE) (468.73 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/de/documents/product-information/potactasol-epar-product-information_de.pdf)

eesti keel (ET) (426.39 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/et/documents/product-information/potactasol-epar-product-information_et.pdf)

ελληνικά (EL) (575.45 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/el/documents/product-information/potactasol-epar-product-information_el.pdf)

français (FR) (478.49 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/fr/documents/product-information/potactasol-epar-product-information_fr.pdf)

hrvatski (HR) (503.34 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/hr/documents/product-information/potactasol-epar-product-information_hr.pdf)

íslenska (IS) (422.78 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/is/documents/product-information/potactasol-epar-product-information_is.pdf)

italiano (IT) (425.28 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/it/documents/product-information/potactasol-epar-product-information_it.pdf)

latviešu valoda (LV) (512.46 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/lv/documents/product-information/potactasol-epar-product-information_lv.pdf)

lietuvių kalba (LT) (504.37 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/lt/documents/product-information/potactasol-epar-product-information_lt.pdf)

magyar (HU) (495.08 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/hu/documents/product-information/potactasol-epar-product-information_hu.pdf)

Malti (MT) (529.09 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/mt/documents/product-information/potactasol-epar-product-information_mt.pdf)

Nederlands (NL) (419.72 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/nl/documents/product-information/potactasol-epar-product-information_nl.pdf)

norsk (NO) (432.98 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/no/documents/product-information/potactasol-epar-product-information_no.pdf)

polski (PL) (553.69 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/pl/documents/product-information/potactasol-epar-product-information_pl.pdf)

português (PT) (438.27 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/pt/documents/product-information/potactasol-epar-product-information_pt.pdf)

română (RO) (525.57 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/ro/documents/product-information/potactasol-epar-product-information_ro.pdf)

slovenčina (SK) (521.46 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/sk/documents/product-information/potactasol-epar-product-information_sk.pdf)

slovenščina (SL) (494.12 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/sl/documents/product-information/potactasol-epar-product-information_sl.pdf)

Suomi (FI) (433.52 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/fi/documents/product-information/potactasol-epar-product-information_fi.pdf)

svenska (SV) (414.06 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

20/01/2025

[View](/sv/documents/product-information/potactasol-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0022 17/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Potactasol : EPAR - All Authorised presentations

English (EN) (21.76 KB - PDF)

**First published:** 17/01/2011

**Last updated:** 17/01/2011

[View](/en/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-10)

български (BG) (93.14 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/bg/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.85 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/es/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_es.pdf)

čeština (CS) (89.81 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/cs/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.29 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/da/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (24.65 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/de/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (22.34 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/et/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (85.63 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/el/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_el.pdf)

français (FR) (25.58 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/fr/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (21.58 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/it/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (85.09 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/lv/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (83.82 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/lt/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.13 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/hu/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (84.95 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/mt/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.74 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/nl/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_nl.pdf)

polski (PL) (90.71 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/pl/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.75 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/pt/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_pt.pdf)

română (RO) (88.03 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/ro/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (54.48 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/sk/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (18.9 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/sl/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (24.07 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/fi/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (24.26 KB - PDF)

**First published:**

17/01/2011

**Last updated:**

17/01/2011

[View](/sv/documents/all-authorised-presentations/potactasol-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Potactasol Active substance topotecan International non-proprietary name (INN) or common name topotecan Therapeutic area (MeSH)

- Uterine Cervical Neoplasms
- Small Cell Lung Carcinoma

Anatomical therapeutic chemical (ATC) code L01CE01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Topotecan monotherapy is indicated for the treatment of:

Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/002282

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Actavis Group PTC ehf

Dalshraun 1 220 Hafnarfjörður Iceland

Opinion adopted 21/10/2010 Marketing authorisation issued 06/01/2011 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Potactasol : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (122.28 KB - PDF)

**First published:** 06/02/2015

**Last updated:** 20/01/2025

[View](/en/documents/procedural-steps-after/potactasol-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Potactasol : EPAR - Public assessment report

English (EN) (243.62 KB - PDF)

**First published:** 17/01/2011

**Last updated:** 17/01/2011

[View](/en/documents/assessment-report/potactasol-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Potactasol

Adopted

Reference Number: EMA/643392/2010

English (EN) (133.65 KB - PDF)

**First published:** 22/10/2010

**Last updated:** 22/10/2010

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-potactasol_en.pdf)

#### More information on Potactasol

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/01/2025

## Share this page

[Back to top](#main-content)